Predrag Sazdanovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Predrag Sazdanovic has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Dejan Baskic
Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
3 shared publications - Dragan Milovanovic
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
3 shared publications - Danijela Todorović
Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2 shared publications Marko Radenkovic
Kragujevac Primary Health Centre, Department of Social Medicine, Kragujevac, Serbia
2 shared publicationsNatasa Djordjevic
University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Kragujevac, Serbia
2 shared publications- Nenad Filipovic
Faculty of Engineering, University of Kragujevac, Sestre Janjić 6, 34000 Kragujevac, Serbia
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 152 (5-6) , 244-253
Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods. The data from the Serbian National Immunization Registry, the Primary Health Centre Report, and the University Clinical Centre Report for Kragujevac, Serbia, for the period from January 1 to March 31, 2021 were used to compare COVID-19 vaccinated population to unvaccinated individuals in terms of laboratory confirmed SARS-CoV-2 infection, COVID-19-related hospitalization and intensive care unit (ICU) admission due to COVID-19. VE was estimated based on the incidence rate ratio, adjusted for age and sex. Results. Overall VE after the first dose reached 20.6%, 28.2%, and 56.1%, and 55.7%, 63.9%, and 79.8%, after the second dose for SARS-CoV-2 infection, COVID-19-related hospitalization, and ICU admission, respectively. BNT162b2 exhibited 96.7% VE against infection and no hospitalization after the second dose. Complete vaccination with BBIBP-CorV and Gam-COVID-Vac demonstrated VE of 43.2% and 78.6% against infection, 56.9% and 85.3% against hospitalization, and 82.3% and 52.7% against ICU admission, respectively. ChAdOx1-nCoV-19 after the first received dose showed VE of 10.3% and 74.7% against infection and hospitalization, with no ICU admission. Conclusion. COVID-19 vaccination in general, as well as each of the four studied vaccines, reduces the risk of SARS-CoV-2 infection, hospitalization due to COVID-19, and COVID-19-related ICU admission. Vaccine effectiveness significantly increases with the second received dose for all study outcomes.
- 1 January 2024
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 152 (5-6) , 244-253
Open AccessEffectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods. The data from the Serbian National Immunization Registry, the Primary Health Centre Report, and the University Clinical Centre Report for Kragujevac, Serbia, for the period from January 1 to March 31, 2021 were used to compare COVID-19 vaccinated population to unvaccinated individuals in terms of laboratory confirmed SARS-CoV-2 infection, COVID-19-related hospitalization and intensive care unit (ICU) admission due to COVID-19. VE was estimated based on the incidence rate ratio, adjusted for age and sex. Results. Overall VE after the first dose reached 20.6%, 28.2%, and 56.1%, and 55.7%, 63.9%, and 79.8%, after the second dose for SARS-CoV-2 infection, COVID-19-related hospitalization, and ICU admission, respectively. BNT162b2 exhibited 96.7% VE against infection and no hospitalization after the second dose. Complete vaccination with BBIBP-CorV and Gam-COVID-Vac demonstrated VE of 43.2% and 78.6% against infection, 56.9% and 85.3% against hospitalization, and 82.3% and 52.7% against ICU admission, respectively. ChAdOx1-nCoV-19 after the first received dose showed VE of 10.3% and 74.7% against infection and hospitalization, with no ICU admission. Conclusion. COVID-19 vaccination in general, as well as each of the four studied vaccines, reduces the risk of SARS-CoV-2 infection, hospitalization due to COVID-19, and COVID-19-related ICU admission. Vaccine effectiveness significantly increases with the second received dose for all study outcomes.
- Open Access
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 82
Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant predominance in Serbia. Methods. The data for the period from Aug 18th to Oct 1st 2021, were used to estimate the incidence rates of the SARS-CoV-2 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission. The study included 41,186 fully vaccinated subjects, of which 13,589 had received the third dose. VE was estimated based on the incidence rate ratio following vaccination with three versus two doses. Results. We found that a third dose of all investigated vaccines reduces the incidence of both SARS-CoV-2 infection and severe illness that requires hospitalization or ICU admission. The highest VE against infection demonstrated BNT162b2, followed by Gam-COVID-Vac and BBIBP-CorV. Third dose vaccination reduced the risk of hospitalization (incidence rate IR = 0 for Gam-COVID-Vac and BBIBP-CorV), and ICU admission (IR = 0 for all vaccines). The hazard distributions for SARS-CoV-2 infection and hospitalization following vaccination with three versus two doses were significantly different. Conclusion. These findings indicate that an additional, third dose of studied vaccine boosters protection against all investigated outcomes.
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 82
Open AccessEffectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant predominance in Serbia. Methods. The data for the period from Aug 18th to Oct 1st 2021, were used to estimate the incidence rates of the SARS-CoV-2 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission. The study included 41,186 fully vaccinated subjects, of which 13,589 had received the third dose. VE was estimated based on the incidence rate ratio following vaccination with three versus two doses. Results. We found that a third dose of all investigated vaccines reduces the incidence of both SARS-CoV-2 infection and severe illness that requires hospitalization or ICU admission. The highest VE against infection demonstrated BNT162b2, followed by Gam-COVID-Vac and BBIBP-CorV. Third dose vaccination reduced the risk of hospitalization (incidence rate IR = 0 for Gam-COVID-Vac and BBIBP-CorV), and ICU admission (IR = 0 for all vaccines). The hazard distributions for SARS-CoV-2 infection and hospitalization following vaccination with three versus two doses were significantly different. Conclusion. These findings indicate that an additional, third dose of studied vaccine boosters protection against all investigated outcomes.
- Open Access
- 30 September 2018
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 12 (09) , 733-740
Chlamydia trachomatis screening in resource-limited countries – Comparison of diagnostic accuracy of 3 different assays
Introduction: Commercially available assays were evaluated in order to determine diagnostic accuracy of Chlamydia trachomatis specific tests for screening. Methods: The study included 225 sexually active men and women, who were tested for genital chlamydial infection in Institute of Public Health Kragujevac. Three screening tests were used: direct immunofluorescence (DIF) and rapid lateral immunochromatographic test (RT) for qualitative detection of chlamydial antigens and immunoenzyme (ELISA) test for detection of serum levels of anti-chlamydial IgA and IgG antibodies. Diagnostic efficiency of these tests were determined in relation to results obtained by RT-PCR method. Results: Statistical significance between the results obtained by RT-PCR as a gold standard and DIF, RT and ELISA were analyzed using chi-square (χ2) test. Statistical analysis showed a significant difference between RT-PCR and analyzed screening tests: DIF (χ2 = 303; p < 0.001), RT (χ2 = 4.19; p = 0.041), serum IgA (χ2 = 4.19; p = 0.041) and serum IgG (χ2 = 67; p < 0.001) which indicates poor agreement between these tests. Large numbers of false positive (FP) and false negative (FN) results were observed for all tested assays. According to Youden’s index, serum IgG and DIF testing demonstrated the most-balanced sensitivity-specificity rate. RT assay exhibits the highest expanded Youden’s index, as well as the best overall diagnostic accuracy. Conclusions: None of evaluated screening tests can be recommended as individual method for the diagnosis of acute infection. We suppose that RT-PCR is unlikely to be a cost-effective screening strategy within the Serbian health system.
- 30 September 2018
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 12 (09) , 733-740
Open AccessChlamydia trachomatis screening in resource-limited countries – Comparison of diagnostic accuracy of 3 different assays
Introduction: Commercially available assays were evaluated in order to determine diagnostic accuracy of Chlamydia trachomatis specific tests for screening. Methods: The study included 225 sexually active men and women, who were tested for genital chlamydial infection in Institute of Public Health Kragujevac. Three screening tests were used: direct immunofluorescence (DIF) and rapid lateral immunochromatographic test (RT) for qualitative detection of chlamydial antigens and immunoenzyme (ELISA) test for detection of serum levels of anti-chlamydial IgA and IgG antibodies. Diagnostic efficiency of these tests were determined in relation to results obtained by RT-PCR method. Results: Statistical significance between the results obtained by RT-PCR as a gold standard and DIF, RT and ELISA were analyzed using chi-square (χ2) test. Statistical analysis showed a significant difference between RT-PCR and analyzed screening tests: DIF (χ2 = 303; p < 0.001), RT (χ2 = 4.19; p = 0.041), serum IgA (χ2 = 4.19; p = 0.041) and serum IgG (χ2 = 67; p < 0.001) which indicates poor agreement between these tests. Large numbers of false positive (FP) and false negative (FN) results were observed for all tested assays. According to Youden’s index, serum IgG and DIF testing demonstrated the most-balanced sensitivity-specificity rate. RT assay exhibits the highest expanded Youden’s index, as well as the best overall diagnostic accuracy. Conclusions: None of evaluated screening tests can be recommended as individual method for the diagnosis of acute infection. We suppose that RT-PCR is unlikely to be a cost-effective screening strategy within the Serbian health system.